#BEGIN_DRUGCARD DB03991

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H17NO8

# Chemical_IUPAC_Name:
(2R,3R,4S)-3-acetamido-4-hydroxy-2-[(1R,2S)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Enzyme Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid

# HET_ID:
DAN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H17NO8/c1-4(14)12-8-5(15)2-7(11(18)19)20-10(8)9(17)6(16)3-13/h2,5-6,8-10,13,15-17H,3H2,1H3,(H,12,14)(H,18,19)/t5-,6-,8+,9+,10+/m0/s1

# InChI_Key:
InChIKey=JINJZWSZQKHCIP-CUZACWQJSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3991

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
291.2546

# Molecular_Weight_Mono:
291.095416525

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1W0O

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.2

# Predicted_LogS:
-0.65

# Predicted_Water_Solubility:
6.52e+01 g/l

# Primary_Accession_No:
DB03991

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
13728878

# PubChem_Substance_ID:
46505061

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01111

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@@H]1[C@@H](O)C=C(O[C@H]1[C@H](O)[C@@H](O)CO)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:50 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type II membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M18764

# Drug_Target_1_GenBank_ID_Protein:
332715

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
HN

# Drug_Target_1_Gene_Sequence:
>1719 bp
ATGGAATACTGGAAGCATACCAATCACGGAAAGGATGCTGGTAATGAGCTGGAGACGTCC
ATGGCTACTCATGGCAACAAGCTCACTAATAAGATAATATACATATTATGGACAATAATC
CTGGTGTTATTATCAATAGTCTTCATCATAGTGCTAATCAATTCCATCAAAAGTGAAAAG
GCCCACGAATCATTGCTGCGAGACATAAACAATGAGTTTATGGAAATTACAGGAAAGATC
CAAATGGCATCGGATAATACCAATGATCTAATACAGTCAGGAGTGAATACAAGGCTTCTT
ACAATTCAGAGTCATGTCCAGAATTACATACCAATATCATTGACACAACAGATGTCAGAT
CTTAGGAAATTCATTAGTGAAATTACAATTAGAAATGATAATCAAGAAGTGCTGCCGCAA
AGAATAACACATGATGTAGGTATAAAACCTTTAAATCCAGATGATTTTTGGAGATGCACG
TCTGGTCTTCCATCTTTAATGAAAACTCCAAAAATAAGGTTAATGCCAGGGCCGGGGTTA
TTAGCTATGCCAACGACTGATGATGGCTGTATTAGAACTCCGTCTTTAGTTATAAATGAT
CTGATTTATGCTTATACCTCAAATCTAATTACTCGAGGTTGTCAGGATATAGGAAAATCA
TATCAAGTCTTACAGATAGGGATAATAACTGTAAACTCAGACTTGGTACCTGACTTAAAT
CCTAGGATCTCTCATACTTTCAACATAAATGACAATAGGAAGTCATGCTCTCTAGCACTC
CTAAATACAGATGTATATCAACTGTGTTCAACTCCCAAAGTTGATGAAAGATCAGATTAT
GCATCATCAGGCATAGAAGATATTGTACTTGATATTGTCAATTATGATGGCTCAATCTCA
ACAACAAGATTTAAGAATAATAACATAAGCTTTGATCAACCATATGCTGCGCTATACCCA
TCTGTTGGACCAGGGATATACTACAAAGGCAAAATAATATTTCTCGGATATGGAGGTCTT
GAACATCCAATAAATGAGAATGTAATCTGCAATACAACTGGGTGTCCCGGGAAAACACAG
AGAGACTGTAATCAAGCGTCTCATAGTCCATGGTTTTCAGATAGGAGGATGGTCAACTCC
ATCATTGTTGTTGACAAAGGCTTAAACTCAACTCCAAAATTGAAGGTATGGACGATATCT
ATGCGACAAAATTACTGGGGGTCAGAAGGAAGGTTACTTCTACTAGGTAACAAGATCTAT
ATATATACAAGATCTACAAGTTGGCATAGCAAGTTACAATTAGGAATAATTGATATTACT
GATTACAGTGATATAAGGATAAAATGGACATGGCATAATGTGCTATCAAGACCAGGAAAC
AATGAATGTCCATGGGGACATTCATGTCCAGATGGATGTATAACAGGAGTATATACTGAT
GCATATCCACTCAATCCCACAGGGAGCATTGTGTCATCTGTCATATTAGACTCACAAAAA
TCGAGAGTGAACCCAGTCATAACTTACTCAACAGCAACCGAAAGAGTAAACGAGCTGGCC
ATCCGAAACAGAACACTCTCAGCTGGATATACAACAACAAGCTGCATTACACACTATAAC
AAAGGATATTGTTTTCATATAGTAGAAATAAATCATAAAAGCTTAAACACATTTCAACCC
ATGTTGTTCAAAACAGAGATTCCAAAAAGCTGCAGTTAA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
2827373	van Wyke Coelingh KL, Winter CC, Murphy BR: Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983. Virology. 1988 Jan;162(1):137-43.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3140

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
64331

# Drug_Target_1_Name:
Hemagglutinin-neuraminidase

# Drug_Target_1_Number_of_Residues:
572

# Drug_Target_1_PDB_ID:
1V3E

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00423	HN

# Drug_Target_1_Protein_Sequence:
>Hemagglutinin-neuraminidase
MEYWKHTNHGKDAGNELETSMATHGNKLTNKIIYILWTIILVLLSIVFIIVLINSIKSEK
AHESLLRDINNEFMEITGKIQMASDNTNDLIQSGVNTRLLTIQSHVQNYIPISLTQQMSD
LRKFISEITIRNDNQEVLPQRITHDVGIKPLNPDDFWRCTSGLPSLMKTPKIRLMPGPGL
LAMPTTDDGCIRTPSLVINDLIYAYTSNLITRGCQDIGKSYQVLQIGIITVNSDLVPDLN
PRISHTFNINDNRKSCSLALLNTDVYQLCSTPKVDERSDYASSGIEDIVLDIVNYDGSIS
TTRFKNNNISFDQPYAALYPSVGPGIYYKGKIIFLGYGGLEHPINENVICNTTGCPGKTQ
RDCNQASHSPWFSDRRMVNSIIVVDKGLNSTPKLKVWTISMRQNYWGSEGRLLLLGNKIY
IYTRSTSWHSKLQLGIIDITDYSDIRIKWTWHNVLSRPGNNECPWGHSCPDGCITGVYTD
AYPLNPTGSIVSSVILDSQKSRVNPVITYSTATERVNELAIRNRTLSAGYTTTSCITHYN
KGYCFHIVEINHKSLNTFQPMLFKTEIPKSCS

# Drug_Target_1_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Neuraminidase activity ensures the efficient spread of the virus by dissociating the mature virions from the neuraminic acid containing glycoproteins

# Drug_Target_1_SwissProt_ID:
P12564

# Drug_Target_1_SwissProt_Name:
HN_PI3HV

# Drug_Target_1_Synonyms:
EC 3.2.1.18

# Drug_Target_1_Theoretical_pI:
7.96

# Drug_Target_1_Transmembrane_Regions:
32-52

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
D01045

# Drug_Target_2_GenBank_ID_Protein:
216784

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
nedA

# Drug_Target_2_Gene_Sequence:
>1944 bp
ATGACTGCGAATCCGTACCTCCGCCGCCTGCCCCGGCGCCGAGCCGTCAGCTTCCTGCTC
GCACCAGCGCTGGCGGCCGCCACGGTCGCCGGCGCGTCCCCCGCACAGGCCATCGCCGGG
GCACCCGTCCCGCCCGGCGGCGAGCCGCTCTACACGGAGCAGGACCTCGCCGTGAACGGC
AGGGAGGGCTTTCCGAACTACCGCATCCCAGCGCTGACCGTCACGCCCGACGGGGACCTG
CTGGCCTCGTACGACGGCCGCCCGACCGGTATCGACGCGCCCGGCCCCAACTCCATCCTC
CAACGCCGCAGCACCGACGGCGGCCGGACGTGGGGCGAGCAACAGGTCGTCAGCGCCGGC
CAGACCACCGCGCCGATCAAGGGGTTCTCCGACCCCAGCTACCTTGTCGACCGGGAAACC
GGGACCATCTTCAACTTCCACGTCTACTCCCAGCGGCAGGGCTTCGCCGGCAGCCGGCCC
GGCACCGACCCGGCAGACCCCAACGTGCTCCACGCCAACGTCGCGACCTCGACCGACGGC
GGTCTGACCTGGTCGCACCGGACCATCACGGCCGACATCACCCCGGATCCGGGCTGGCGC
AGCCGCTTCGCCGCCTCCGGCGAAGGCATCCAGCTCCGCTATGGACCCCACGCCGGTCGA
CTCATCCAGCAGTACACGATCATCAACGCTGCCGGCGCCTTCCAGGCGGTGAGCGTGTAC
AGCGACGACCACGGAAGGACCTGGCGCGCCGGCGAAGCCGTCGGGGTCGGCATGGACGAG
AACAAGACCGTGGAACTCTCCGATGGCCGGGTCCTGCTCAACAGCCGCGACTCGGCCCGC
AGCGGATACCGTAAGGTGGCCGTCTCCACTGACGGCGGCCACAGCTACGGCCCGGTGACC
ATCGACCGCGACCTCCCCGACCCGACGAACAACGCATCGATCATCCGGGCCTTCCCTGAC
GCCCCGGCCGGCTCCGCGCGGGCCAAGGTCCTGCTCTTCTCCAACGCCGCCAGCCAGACC
TCGCGCAGTCAGGGCACCATCCGGATGTCCTGCGACGATGGCCAGACCTGGCCGGTTTCG
AAGGTCTTCCAGCCCGGCTCGATGTCGTACTCCACCCTGACCGCACTGCCCGACGGCACC
TACGGGCTGCTGTACGAGCCGGGCACCGGCATCAGATACGCCAACTTCAACCTCGCCTGG
CTGGGCGGCATCTGCGCGCCCTTCACGATTCCGGATGTGGCGCTCGAGCCGGGCCAGCAG
GTCACTGTTCCGGTGGCCGTCACGAACCAGTCCGGTATCGCGGTACCGAAGCCGAGCCTT
CAGCTCGACGCATCGCCGGACTGGCAGGTTCAGGGTTCCGTCGAGCCCCTCATGCCCGGA
CGGCAGGCCAAGGGCCAGGTGACCATCACGGTTCCCGCCGGCACCACCCCCGGTCGCTAC
CGGGTCGGTGCGACGCTGCGCACCTCCGCGGGTAACGCGTCGACGACCTTCACGGTCACG
GTTGGACTGCTCGACCAGGCCCGGATGAGCATCGCGGACGTCGACAGCGAGGAGACCGCC
CGCGAAGACGGGCGGGCGAGCAACGTGATCGACGGCAACCCCTCGACGTTCTGGCACACC
GAATGGTCGCGTGCCGATGCTCCTGGCTACCCGCACCGCATCAGCCTCGACCTCGGTGGC
ACGCACACGATCAGCGGCCTCCAGTACACCCGACGGCAGAACAGCGCCAACGAGCAGGTC
GCGGACTACGAGATCTACACCAGCCTGAACGGCACGACCTGGGATGGCCCGGTTGCCAGC
GGGCGCTTCACCACGTCCCTCGCGCCGCAGCGCGCGGTCTTCCCGGCGCGGGACGCCAGG
TACATCCGGTTGGTGGCCCTCAGCGAGCAGACCGGGCACAAGTACGCCGCGGTCGCTGAG
CTGGAGGTGGAAGGCCAGCGCTGA

# Drug_Target_2_General_Function:
Involved in exo-alpha-sialidase activity

# Drug_Target_2_General_References:
1400240	Sakurada K, Ohta T, Hasegawa M: Cloning, expression, and characterization of the Micromonospora viridifaciens neuraminidase gene in Streptomyces lividans. J Bacteriol. 1992 Nov;174(21):6896-903.
8591030	Gaskell A, Crennell S, Taylor G: The three domains of a bacterial sialidase: a beta-propeller, an immunoglobulin module and a galactose-binding jelly-roll. Structure. 1995 Nov 15;3(11):1197-205.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3546

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
68831

# Drug_Target_2_Name:
Sialidase

# Drug_Target_2_Number_of_Residues:
647

# Drug_Target_2_PDB_ID:
1EUU

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00754	F5_F8_type_C
PF02012	BNR

# Drug_Target_2_Protein_Sequence:
>Sialidase precursor
MTANPYLRRLPRRRAVSFLLAPALAAATVAGASPAQAIAGAPVPPGGEPLYTEQDLAVNG
REGFPNYRIPALTVTPDGDLLASYDGRPTGIDAPGPNSILQRRSTDGGRTWGEQQVVSAG
QTTAPIKGFSDPSYLVDRETGTIFNFHVYSQRQGFAGSRPGTDPADPNVLHANVATSTDG
GLTWSHRTITADITPDPGWRSRFAASGEGIQLRYGPHAGRLIQQYTIINAAGAFQAVSVY
SDDHGRTWRAGEAVGVGMDENKTVELSDGRVLLNSRDSARSGYRKVAVSTDGGHSYGPVT
IDRDLPDPTNNASIIRAFPDAPAGSARAKVLLFSNAASQTSRSQGTIRMSCDDGQTWPVS
KVFQPGSMSYSTLTALPDGTYGLLYEPGTGIRYANFNLAWLGGICAPFTIPDVALEPGQQ
VTVPVAVTNQSGIAVPKPSLQLDASPDWQVQGSVEPLMPGRQAKGQVTITVPAGTTPGRY
RVGATLRTSAGNASTTFTVTVGLLDQARMSIADVDSEETAREDGRASNVIDGNPSTFWHT
EWSRADAPGYPHRISLDLGGTHTISGLQYTRRQNSANEQVADYEIYTSLNGTTWDGPVAS
GRFTTSLAPQRAVFPARDARYIRLVALSEQTGHKYAAVAELEVEGQR

# Drug_Target_2_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_2_Signals:
1-37

# Drug_Target_2_Specific_Function:
To release sialic acids for use as carbon and energy sources for this non-pathogenic bacterium while in pathogenic microorganisms, sialidases have been suggested to be pathogenic factors

# Drug_Target_2_SwissProt_ID:
Q02834

# Drug_Target_2_SwissProt_Name:
NANH_MICVI

# Drug_Target_2_Synonyms:
EC 3.2.1.18
Neuraminidase
Sialidase precursor

# Drug_Target_2_Theoretical_pI:
6.52

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Virion
apical cell membrane
single-pass type II membrane protein (
virion membrane. Cell membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M11445

# Drug_Target_3_GenBank_ID_Protein:
324416

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
NA

# Drug_Target_3_Gene_Sequence:
>1413 bp
ATGAATCCAAATCAGAAGATTCTATGCACTTCTGCCACTGCTCTCGTAATAGGCACAATT
GCAGTACTCATAGGAATAACGAACTTAGGATTGAACATAGGACTACATCTGAAACCGAGC
TGCAATTGCTCACACTCACAACCCGAAGCAACCAATGCAAGCCAAACAATAATAAATAAC
TATTATAATGACACAAACATCACCCAGATAAGTAATACCAACATTCAGGTAGAGGAAAGG
GCAATTAGAGATTTCAATAACTTGACCAAAGGGCTCTGTACTATAAATTCATGGCACATA
TATGGGAAAGACAATGCGGTGAGAATTGGGGAGGACTCAGATGTTTTAGTCACAAGAGAA
CCCTATGTCTCCTGTGACCCAGATGAGTGCAGGTTCTATGCTCTCAGCCAAGGGACAACA
ATCAGAGGAAAACACTCAAATGGAACAATACACGATAGGTCTCAATATCGTGCCCTGATA
AGCTGGCCATTGTCATCACCGCCCACAGTATACAACAGCAGAGTGGAATGCATTGGATGG
TCAAGTACTAGTTGTCATGATGGCAAAACCAGGATGTCAATATGCATATCAGGCCCGAAC
AATAACGCATCAGCAGTGATCTGGTACAATAGAAGGCCTGTGACAGAAATCAACACATGG
GCCCGAAACATACTAAGGACACAAGAATCTGAATGCGTATGCCACAACGGTGTCTGCCCG
GTAGTGTTCACAGATGGGTCTGCCACTGGACCTGCAGAAACAAGAATATACTATTTTAAA
GAAGGGAAGATCTTAAAATGGGAACCTCTGGCTGGAACTGCTAAGCATATCGAAGAATGC
TCATGCTACGGAGAGCGAGCAGAGATTACTTGCACGTGTAGGGATAATTGGCAAGGCTCA
AATAGACCAGTAATTCGGATAGATCCAGTGGCGATGACACATACTAGTCAGTATATATGT
AGCCCTGTTCTCACAGATAACCCCCGACCGAATGACCCAACTGTAGGTAAGTGTAACGAC
CCTTATCCAGGCAATAACAACAATGGGGTCAAAGGGTTTTCATATCTGGATGGAGTTAAT
ACTTGGCTAGGGAGGACAATAAGCATAGCTTCAAGATCCGGATATGAGATGCTAAAGGTG
CCAAATGCATTGACAGACGATAAGTCAAAGCCCACTCAAGGTCAGACAATCGTCTTAAAC
ACTGACTGGAGTGGTTACAGTGGGTCCTTCATGGACTATTGGGCTGAGGGGGAATGCTAC
CGAGCGTGTTTTTACGTGGAGTTAATACGTGGGAGACCTAAGGAGGATAAAGTGTGGTGG
ACCAGTAATAGTATAGTATCGATGTGTTCCAGCACAGAATTCCTTGGACAATGGGACTGG
CCTGATGGGGCTAAAATAGAGTACTTCCTCTAA

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
3447170	Baker AT, Varghese JN, Laver WG, Air GM, Colman PM: Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins. 1987;2(2):111-7.
3660585	Air GM, Webster RG, Colman PM, Laver WG: Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. Virology. 1987 Oct;160(2):346-54.
4013081	Air GM, Ritchie LR, Laver WG, Colman PM: Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity. Virology. 1985 Aug;145(1):117-22.
8371267	Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM: Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol. 1993 Aug 20;232(4):1069-83.
9342319	Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL: Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3026

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
52469

# Drug_Target_3_Name:
Neuraminidase

# Drug_Target_3_Number_of_Residues:
470

# Drug_Target_3_PDB_ID:
1NMB

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_3_Protein_Sequence:
>Neuraminidase
MNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEATNASQTIINN
YYNDTNITQISNTNIQVEERAIRDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTRE
PYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALISWPLSSPPTVYNSRVECIGW
SSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCP
VVFTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGS
NRPVIRIDPVAMTHTSQYICSPVLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVN
TWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNTDWSGYSGSFMDYWAEGECY
RACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL

# Drug_Target_3_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication

# Drug_Target_3_SwissProt_ID:
P03472

# Drug_Target_3_SwissProt_Name:
NRAM_I75A5

# Drug_Target_3_Synonyms:
EC 3.2.1.18

# Drug_Target_3_Theoretical_pI:
6.57

# Drug_Target_3_Transmembrane_Regions:
7-35

# Drug_Target_4_Cellular_Location:
Membrane
single-pass type II membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
X04355

# Drug_Target_4_GenBank_ID_Protein:
60936

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
HN

# Drug_Target_4_Gene_Sequence:
>1734 bp
ATGGACCGCGCAGTTAGCCAAGTTGCGTTAGAGAATGATGAAAGAGAGGCAAAAAATACA
TGGCGCTTGATATTCCGGATTGCAATCTTACTCTTAACAGTAGTGACCTTAGCTACATCT
GTAGCCTCCCTTGTATATAGCATGGGGGCTAGCACACCTAGCGACCTTGTAGGCATACCG
ACCAGGATTTCTAGGGCAGAAGAAAAGATTACATCTGCACTTGGTTCCAATCAAGATGTA
GTAGATAGGATATATAAGCAAGTGGCCCTTGAGTCTCCGTTGGCATTGTTAAACACTGAG
ACCACAATTATGAACGCAATAACATCTCTCTCTTATCAGATTAATGGAGCTGCGAACAAC
AGCGGGTGGGGGGCACCTATCCATGACCCAGATTTTATCGGGGGGATAGGCAAAGAACTC
ATTGTAGATGATGCTAGTGATGTCACATCATTCTATCCCTCTGCATTTCAAGAACATCTG
AATTTTATCCCGGCGCCTACTACAGGATCAGGTTGCACTCGGATACCTTCATTTGACATG
AGTGCTACCCATTACTGCTACACTCATAATGTAATATTGTCTGGATGCAGAGATCACTCA
CACTCACATCAGTATTTAGCACTTGGTGTGCTCCGGACAACTGCAACAGGGAGGATATTC
TTTTCTACTCTGCGTTCCATCAGTCTGGATGACACCCAAAATCGGAAGTCTTGCAGTGTG
AGTGCAACTCCCTTAGGTTGTGATATGCTGTGCTCGAAAGTCACGGAGACAGAGGAAGAA
GATTATAACTCAGCTGTCCCTACGCTGATGGCACATGGGAGGTTAGGGTTCGACGGCCAA
TACCACGAAAAGGACCTAGACGTCACAACATTATTTGAGGACTGGGTGGCCAACTACCCA
GGAGTAGGGGGTGGATCTTTTATTGACGGCCGCGTATGGTTCTCAGTCTACGGAGGGCTG
AAACCCAATTCACCCAGTGACACTGTACAGGAAGGGAAATATGTAATATACAAGCGATAC
AATGACACATGCCCAGATGAGCAAGACTACCAGATCCGAATGGCCAAGTCTTCGTATAAG
CCCGGGCGGTTTGGTGGGAAACGCATACAGCAGGCTATCTTATCTATCAAGGTGTCAACA
TCTTTGGGCGAAGACCCAGTACTGACTGTACCGCCCAACACAGTCACACTCATGGGGGCC
GAAGGCAGAATTCTCACAGTAGGGACATCTCATTTCTTGTATCAGCGAGGGTCATCATAC
TTCTCTCCCGCGTTATTATATCCTATGACAGTCAGCAACAAAACAGCCACTCTTCATAGT
CCCTATACATTCAATGCCTTCACTCGGCCAGGTAGTATCCCTTGCCAGGCTTCAGCAAGA
TGCCCCAACTCGTGTGTTACTGGAGTCTATACAGATCCATATCCCCTAATCTTCTATAGG
AACCACACCTTGCGAGGGGTATTCGGGACAATGCTTGATAGTGAACAAGCAAGACTTAAT
CCTACGTCTGCAGTATTCGATAGCACATCCCGCAGTCGCATAACTCGAGTGAGTTCAAGC
AGCACCAAAGCAGCATACACAACATCAACTTGTTTTAAAGTTGTCAAGACCAATAAGACC
TATTGTCTCAGCATTGCTGAAATATCTAATACTCTCTTCGGAGAATTCAGAATCGTCCCG
TTACTAGTTGAGATCCTCAAAAATGATGGGGTTAGAGAAGCCAGGTCTGGTTAG

# Drug_Target_4_General_Function:
Not Available

# Drug_Target_4_General_References:
2705297	Sakaguchi T, Toyoda T, Gotoh B, Inocencio NM, Kuma K, Miyata T, Nagai Y: Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene. Virology. 1989 Apr;169(2):260-72.
3018130	Millar NS, Chambers P, Emmerson PT: Nucleotide sequence analysis of the haemagglutinin-neuraminidase gene of Newcastle disease virus. J Gen Virol. 1986 Sep;67 ( Pt 9):1917-27.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3609

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
63143

# Drug_Target_4_Name:
Hemagglutinin-neuraminidase

# Drug_Target_4_Number_of_Residues:
577

# Drug_Target_4_PDB_ID:
1USR

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00423	HN

# Drug_Target_4_Protein_Sequence:
>Hemagglutinin-neuraminidase
MDRAVSQVALENDEREAKNTWRLIFRIAILLLTVVTLATSVASLVYSMGASTPSDLVGIP
TRISRAEEKITSALGSNQDVVDRIYKQVALESPLALLNTETTIMNAITSLSYQINGAANN
SGWGAPIHDPDFIGGIGKELIVDDASDVTSFYPSAFQEHLNFIPAPTTGSGCTRIPSFDM
SATHYCYTHNVILSGCRDHSHSHQYLALGVLRTTATGRIFFSTLRSISLDDTQNRKSCSV
SATPLGCDMLCSKVTETEEEDYNSAVPTLMAHGRLGFDGQYHEKDLDVTTLFEDWVANYP
GVGGGSFIDGRVWFSVYGGLKPNSPSDTVQEGKYVIYKRYNDTCPDEQDYQIRMAKSSYK
PGRFGGKRIQQAILSIKVSTSLGEDPVLTVPPNTVTLMGAEGRILTVGTSHFLYQRGSSY
FSPALLYPMTVSNKTATLHSPYTFNAFTRPGSIPCQASARCPNSCVTGVYTDPYPLIFYR
NHTLRGVFGTMLDSEQARLNPTSAVFDSTSRSRITRVSSSSTKAAYTTSTCFKVVKTNKT
YCLSIAEISNTLFGEFRIVPLLVEILKNDGVREARSG

# Drug_Target_4_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Neuraminidase activity ensures the efficient spread of the virus by dissociating the mature virions from the neuraminic acid containing glycoproteins

# Drug_Target_4_SwissProt_ID:
P32884

# Drug_Target_4_SwissProt_Name:
HN_NDVB

# Drug_Target_4_Synonyms:
EC 3.2.1.18

# Drug_Target_4_Theoretical_pI:
7.09

# Drug_Target_4_Transmembrane_Regions:
27-48

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
D50685

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
TCTS-154

# Drug_Target_5_Gene_Sequence:
>3183 bp
ATGGGGAAAACAGTCGTTGGGGCCAGTAGGATGTTCTGGCTAATGTTTTTCGTGCCGCTT
CTTCTTGCGCTCTGCCCCAGCGAGCCCGCGCATGCCCTGGCACCCGGATCGAGCCGAGTT
GAGCTGTTTAAGCGGCAAAGCTCGAAGGTGCCATTTGAAAAGGGCGGCAAAGTCACCGAG
CGGGTTGTCCACTCGTTCCGCCTCCCCGCCCTTGTTAATGTGGACGGGGTGATGGTTGCC
ATCGCGGACGCTCGCTACGAAACATCCAATGACAACTCCCTCATTGATACGGTGGCGAAG
TACAGCGTGGACGATGGGGAGACGTGGGAGACCCAAATTGCCATCAAGAACAGTCGTGCA
TCGTCTGTTTCTCGTGTGGTGGATCCCACAGTGATTGTGAAGGGCAACAAGCTTTACGTC
CTGGTTGGAAGCTACAACAGTTCGAGGAGCTACTGGACGTCGCATGGTGATGCGAGAGAC
TGGGATATTCTGCTTGCCGTTGGTGAGGTCACGAAGTCCACTGCGGGCGGCAAGATAACT
GCGAGTATCAAATGGGGGAGCCCCGTGTCACTGAAGGAATTTTTCCCGGCGGAAATGGAA
GGAATGCACACAAATCAATTTCTTGGCGGTGCAGGTGTTGCCATTGTGGCGTCCAACGGG
AATCTTGTGTACCCTGTGCAGGTTACGAACAAAAAGAAGCAAGTTTTTTCCAAGATCTTC
TACTCGGAAGACGAGGGCAAGACGTGGAAGTTTGGGGAGGGTAGGAGTGATTTTGGCTGC
TCTGAACCTGTGGCCCTTGAGTGGGAGGGGAAGCTCATCATAAACACTCGAGTTGACTAT
CGCCGCCGTCTGGTGTACGAGTCCAGTGACATGGGGAATTCGTGGGTGGAGGCTGTCGGC
ACGCTCTCACGTGTGTGGGGCCCCTCACCAAAATCGAACCAGCCCGGCAGTCAGAGCAGC
TTCACTGCCGTGACCATCGAGGGAATGCGTGTTATGCTCTTCACACACCCGCTGAATTTT
AAGGGAAGGTGGCTGCGCGACCGACTGAACCTCTGGCTGACGGATAACCAGCGCATTTAT
AACGTTGGGCAAGTATCCATTGGTGATGAAAATTCCGCCTACAGCTCCGTCCTGTACAAG
GATGATAAGCTGTACTGTTTGCATGAGATCAACAGTAACGAGGTGTACAGCCTTGTTTTT
GCGCGCCTGGTTGGCGAGCTACGGATCATTAAATCAGTGCTGCAGTCCTGGAAGAATTGG
GACAGCCACCTGTCCAGCATTTGCACCCCTGCTGATCCAGCCGCTTCGTCGTCAGAGCGT
GGTTGTGGTCCCGCTGTCACCACGGTTGGTCTTGTTGGCTTTTTGTCGCACAGTGCCACC
AAAACCGAATGGGAGGATGCGTACCGCTGCGTCAACGCAAGCACGGCAAATGCGGAGAGG
GTTCCGAACGGTTTGAAGTTTGCGGGGGTTGGCGGAGGGGCGCTTTGGCCGGTGAGCCAG
CAGGGGCAGAATCAACGGTATCACTTTGCAAACCACGCGTTCACGCTGGTGGCGTCGGTG
ACGATTCACGAGGTTCCGAGCGTCGCGAGTCCTTTGCTGGGTGCGAGCCTGGACTCTTCT
GGTGGCAAAAAACTCCTGGGGCTCTCGTACGACGAGAAGCACCAGTGGCAGCCAATATAC
GGATCAACGCCGGTGACGCCGACCGGATCGTGGGAGATGGGTAAGAGGTACCACGTGGTT
CTTACGATGGCGAATAAAATTGGTTCGGTGTACATTGATGGAGAACCTCTGGAGGGTTCA
GGGCAGACCGTTGTGCCAGACGGGAGGACGCCTGACATCTCCCACTTCTACGTTGGCGGG
TATGGAAGGAGTGATATGCCAACCATAAGCCACGTGACGGTGAATAATGTTCTTCTTTAC
AACCGTCAGCTGAATGCCGAGGAGATCAGGACCTTGTTCTTGAGCCAGGACCTGATTGGC
ACGGAAGCACACATGGGCAGCAGCAGCGGCAGCAGTGCCCACAGTACGCCCTCAACTCCC
GCTGACAACGGTGCCCACAGTACGCCCTCAACTCCCGCTGACAGCAGTGCCCACAGTACG
CCCTCAACTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCGACTCCCGGTGACAGCAGTGCCCACAGTACGCCCTCAACTCCC
GCTGACAACGGTGCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAATGCCCACAGTACG
CCCTCGACTCCCGCTGACAACGGTGCCCACAGTACGCCCTCAACTCCCGCTGACAACGGT
GCCCACAGTACGCCCTCGACTCCCGGTGACAACGGTGCCCACAGTACGCCCTCGACTCCC
GGTGACAGCAGTGCCCACAGTACGCCCTCAACTCCCGCTGACAACGGTGCCCACAGTACG
CCCTCAGCTCCCGCTGACAGCAATGCCCACAGTACGCCCTCGACTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAATGCCCACAGTACGCCCTCGACTCCC
GCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGTGCCCACAGTACG
CCCTCAGCTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCAGCTCCCGCTGACAACGGTGCCCACAGTACGCCCTCAGCTCCC
GGTGACAGCAATGCCCACAGTACGCCCTCGACTCCCGCTGACAGCAGTGCCCACAGTACG
CCCTCAACTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAATTCCC
GGTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAGTGCCCACAGTACG
CCCTCAGCTCCCGGTGACAACGGTGCCCACAGTACGCCCTCGACTCCCGCTGACAACGGC
GCTAATGGTACGGTTTTGATTTTGCACGATGGCGCTGCATTTTCGGCCTTTTCGGGCGGA
GGGCTTCTTTTGTGTGCGGGTGCTTTGCTGCTGCACGTGTTCGTTATGGCAGTTTTTTTC
TGA

# Drug_Target_5_General_Function:
Involved in exo-alpha-sialidase activity

# Drug_Target_5_General_References:
12419220	Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM: The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell. 2002 Oct;10(4):757-68.
1396577	Uemura H, Schenkman S, Nussenzweig V, Eichinger D: Only some members of a gene family in Trypanosoma cruzi encode proteins that express both trans-sialidase and neuraminidase activities. EMBO J. 1992 Nov;11(11):3837-44.
8844669	Smith LE, Uemura H, Eichinger D: Isolation and expression of an open reading frame encoding sialidase from Trypanosoma rangeli. Mol Biochem Parasitol. 1996 Jul;79(1):21-33.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
5481

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
110104

# Drug_Target_5_Name:
Trans-sialidase

# Drug_Target_5_Number_of_Residues:
1060

# Drug_Target_5_PDB_ID:
1S0K

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF02012	BNR

# Drug_Target_5_Protein_Sequence:
>Trans-sialidase
MGKTVVGASRMFWLMFFVPLLLALCPSEPAHALAPGSSRVELFKRQSSKVPFEKGGKVTE
RVVHSFRLPALVNVDGVMVAIADARYETSNDNSLIDTVAKYSVDDGETWETQIAIKNSRA
SSVSRVVDPTVIVKGNKLYVLVGSYNSSRSYWTSHGDARDWDILLAVGEVTKSTAGGKIT
ASIKWGSPVSLKEFFPAEMEGMHTNQFLGGAGVAIVASNGNLVYPVQVTNKKKQVFSKIF
YSEDEGKTWKFGEGRSDFGCSEPVALEWEGKLIINTRVDYRRRLVYESSDMGNSWVEAVG
TLSRVWGPSPKSNQPGSQSSFTAVTIEGMRVMLFTHPLNFKGRWLRDRLNLWLTDNQRIY
NVGQVSIGDENSAYSSVLYKDDKLYCLHEINSNEVYSLVFARLVGELRIIKSVLQSWKNW
DSHLSSICTPADPAASSSERGCGPAVTTVGLVGFLSHSATKTEWEDAYRCVNASTANAER
VPNGLKFAGVGGGALWPVSQQGQNQRYHFANHAFTLVASVTIHEVPSVASPLLGASLDSS
GGKKLLGLSYDEKHQWQPIYGSTPVTPTGSWEMGKRYHVVLTMANKIGSVYIDGEPLEGS
GQTVVPDGRTPDISHFYVGGYGRSDMPTISHVTVNNVLLYNRQLNAEEIRTLFLSQDLIG
TEAHMGSSSGSSAHSTPSTPADNGAHSTPSTPADSSAHSTPSTPADSSAHSTPSAPGDNG
AHSTPSTPGDSSAHSTPSTPADNGAHSTPSAPADSNAHSTPSTPADNGAHSTPSTPADNG
AHSTPSTPGDNGAHSTPSTPGDSSAHSTPSTPADNGAHSTPSAPADSNAHSTPSTPGDNG
AHSTPSAPADSNAHSTPSTPADSSAHSTPSAPGDNGAHSTPSAPADSSAHSTPSAPGDNG
AHSTPSAPADNGAHSTPSAPGDSNAHSTPSTPADSSAHSTPSTPADSSAHSTPSAPGDNG
AHSTPSAPADSSAHSTPSIPGDSSAHSTPSAPADSSAHSTPSAPGDNGAHSTPSTPADNG
ANGTVLILHDGAAFSAFSGGGLLLCAGALLLHVFVMAVFF

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
Q26964

# Drug_Target_5_SwissProt_Name:
Q26964_TRYCR

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
6.27

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
NEU2

# Drug_Target_6_GenBank_ID_Gene:
Y16535

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
NEU2

# Drug_Target_6_Gene_Sequence:
>1143 bp
ATGGCGTCCCTTCCTGTCCTGCAGAAGGAGAGCGTGTTCCAGTCGGGAGCCCATGCCTAC
AGAATCCCTGCCCTGCTCTACCTGCCTGGGCAGCAGTCCCTGCTGGCCTTCGCGGAACAG
CGGGCAAGCAAGAAGGATGAGCACGCAGAGCTGATTGTCCTGCGCAGAGGAGACTACGAC
GCACCCACCCACCAGGTTCAGTGGCAAGCTCAGGAGGTGGTGGCCCAGGCCCGGCTGGAT
GGCCACCGGTCCATGAACCCATGCCCCTTGTATGACGCGCAGACGGGGACCCTCTTCCTC
TTCTTCATTGCCATCCCTGGGCAAGTCACGGAGCAACAGCAGCTGCAGACCAGGGCCAAT
GTGACGCGGCTGTGCCAAGTCACCAGCACTGACCACGGGAGGACCTGGAGCTCCCCCAGA
GACCTCACTGATGCGGCCATCGGCCCAGCCTACCGGGAGTGGTCCACCTTTGCAGTGGGC
CCGGGGCATTGTTTGCAGCTTAACGACAGGGCCCGGAGCCTGGTGGTGCCCGCCTACGCC
TACCGGAAACTTCACCCCATCCAAAGGCCGATCCCCTCTGCCTTCTGCTTCCTCAGCCAT
GACCATGGGCGCACGTGGGCGCGAGGGCACTTTGTGGCCCAGGACACCCTGGAGTGCCAG
GTGGCCGAAGTCGAGACTGGGGAGCAGAGGGTGGTGACCCTCAACGCGAGAAGCCACCTC
CGAGCCAGGGTCCAGGCCCAGAGCACCAATGACGGGCTTGATTTCCAGGAGTCTCAGCTG
GTGAAGAAGCTGGTGGAGCCGCCGCCCCAGGGCTGCCAGGGGAGCGTCATCAGCTTCCCC
AGCCCCCGCTCGGGGCCTGGCTCCCCAGCCCAGTGGCTGCTCTACACTCACCCCACACAC
TCCTGGCAGAGGGCCGACCTGGGTGCCTACCTCAACCCGCGACCTCCAGCCCCTGAGGCC
TGGTCAGAGCCGGTACTGCTGGCCAAGGGCAGCTGTGCCTACTCAGACCTCCAGAGCATG
GGCACCGGCCCTGATGGGTCCCCCTTGTTTGGGTGTCTGTACGAAGCCAATGATTACGAG
GAGATTGTCTTTCTCATGTTCACCCTGAAGCAAGCCTTCCCAGCTGAGTACCTGCCTCAG
TGA

# Drug_Target_6_General_Function:
Not Available

# Drug_Target_6_General_References:
10191093	Monti E, Preti A, Rossi E, Ballabio A, Borsani G: Cloning and characterization of NEU2, a human gene homologous to rodent soluble sialidases. Genomics. 1999 Apr 1;57(1):137-43.

# Drug_Target_6_HGNC_ID:
HGNC:7759

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
5482

# Drug_Target_6_Locus:
2q37

# Drug_Target_6_Molecular_Weight:
42231

# Drug_Target_6_Name:
Sialidase-2

# Drug_Target_6_Number_of_Residues:
380

# Drug_Target_6_PDB_ID:
1VCU

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF02012	BNR

# Drug_Target_6_Protein_Sequence:
>Sialidase-2
MASLPVLQKESVFQSGAHAYRIPALLYLPGQQSLLAFAEQRASKKDEHAELIVLRRGDYD
APTHQVQWQAQEVVAQARLDGHRSMNPCPLYDAQTGTLFLFFIAIPGQVTEQQQLQTRAN
VTRLCQVTSTDHGRTWSSPRDLTDAAIGPAYREWSTFAVGPGHCLQLNDRARSLVVPAYA
YRKLHPIQRPIPSAFCFLSHDHGRTWARGHFVAQDTLECQVAEVETGEQRVVTLNARSHL
RARVQAQSTNDGLDFQESQLVKKLVEPPPQGCQGSVISFPSPRSGPGSPAQWLLYTHPTH
SWQRADLGAYLNPRPPAPEAWSEPVLLAKGSCAYSDLQSMGTGPDGSPLFGCLYEANDYE
EIVFLMFTLKQAFPAEYLPQ

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Hydrolyzes sialylated compounds

# Drug_Target_6_SwissProt_ID:
Q9Y3R4

# Drug_Target_6_SwissProt_Name:
NEUR2_HUMAN

# Drug_Target_6_Synonyms:
Cytosolic sialidase
EC 3.2.1.18
N-acetyl-alpha- neuraminidase 2

# Drug_Target_6_Theoretical_pI:
6.83

# Drug_Target_6_Transmembrane_Regions:
None

#END_DRUGCARD DB03991
